Nov 7, 2019 ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease
Oct 24, 2019 ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease
Oct 17, 2019 ProMIS Neurosciences advances Alzheimer’s disease program targeting neurotoxic forms of tau
Oct 17, 2019 ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau
Sep 16, 2019 ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit
Aug 27, 2019 ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer’s Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board